Lentivectors to the rescue of a stalling retroviral vector field
Retrovirologists realized long ago that they held a tool having many of the characteristics of a formidable gene delivery system. First, retroviral vectors have a large cloning capacity, close to 10 kb. Second, they integrate their cargo into the chromosomes of target cells, a likely prerequisite for long-term expression. Third, they do not transfer virus-derived coding sequence, avoiding the recognition and destruction of transduced cells by vectorspecific cytotoxic T lymphocytes. In spite of these impressive assets, however, retroviral vectors encountered a colossal obstacle -derived from oncoretroviruses such as Moloney murine leukemia virus (MoMLV), they could not transfer genes into cells that do not divide within the next few hours. 1 ,2 Yet most of the potential targets of gene therapy are cells that rarely if ever proliferate, be they neurons, hepatocytes, myocytes or hematopoietic stem cells.
In contrast to oncoretroviruses, lentiviruses such as the human immunodeficiency virus type 1 (HIV-1) can replicate in non-mitotic cells because their so-called preintegration complex, a macromolecular structure comprising the viral genome, a few structural proteins and the enzymes responsible for reverse transcription and integration, hijacks the cell nuclear import machinery. [3] [4] [5] Docking at the nuclear envelope and energy-dependent transport through the nucleopore ensue, allowing infection of cells such as lowly activated T lymphocytes and terminally differentiated macrophages. The determinants of this property have been assigned to specific viral constituents that play both additive and redundant roles: for Correspondence: D Trono has led to this rapid development and describes the current state of the art in the design and production of lentiviral vectors. The important question of biosafety is discussed. This system seems to have the edge over other gene delivery tools for particular targets, however, there remain several issues to be resolved before lentivectors make it to the bedside. Gene Therapy (2000) 7, 20-23.
HIV-1, matrix (MA), virion protein R (VPR) and integrase (IN).
6-9 Logically, many laboratories attempted to transfer these determinants to oncoretroviral vectors, hoping to render the latter capable of transducing nondividing cells. However, this met with no success, probably due to the intricacy and specificity of the interactions involved in making a functional lentiviral preintegration complex. As the sophistication of this process was becoming more obvious, a group of us took the option of developing a vector straight from the best characterized of all lentiviruses, HIV-1. Capitalizing on an already refined understanding of HIV-1 molecular biology, on previous work on the topic 35 and on parallel progress in the gene transfer area (for instance the demonstration that pseudotyping retroviral particles with the G envelope of vesicular stomatitis virus yields very high titer vector stocks), 10 this effort led to the 'proof of concept' that lentiviral vectors can mediate the efficient in vivo delivery, stable integration and long-term expression of transgenes into non-mitotic cells such as neurons. 11 Broad perspectives were opened, although it was clear that the original configuration of HIV-derived vectors, much too close to that of their dreadful parent, precluded any clinical use.
Current state of the art in lentiviral vector design and biosafety
The subsequent development of lentiviral vectors was facilitated by the knowledge recently accumulated while studying their oncoretroviral predecessors. Lentivector particles are generated by co-expressing the virion packaging elements and the vector genome in, for instance, a 293 human embryonic kidney cell which serves as a producer. 1 In the case of HIV-1-based vectors, the core and enzymatic components of the virion come from HIV-1, while the envelope is derived from a heterologous virus, most often VSV due to the high stability and broad tropism of its G protein. The genomic complexity of HIV, where a whole set of genes encodes virulence factors essential for pathogenesis but not necessary for transferring the virus genetic cargo, allowed a major step towards a clinically acceptable system. [12] [13] [14] Multiply attenuated packaging systems could indeed be created, the latest ('third') generation of which comprises only three of the nine genes of HIV-1: gag, coding for the virion main structural proteins; pol, responsible for the retrovirus-specific enzymes; and rev, which encodes a post-transcriptional regulator necessary for efficient gag and pol expression. 13 The parental virus cannot be reconstituted from such an extensively deleted packaging system since some 60% of its genome has been completely eliminated.
The vector itself is the only genetic material transferred to the target cells. It typically comprises the transgene cassette flanked by cis-acting elements necessary for its encapsidation, reverse transcription and integration. As was done previously with oncoretroviral vectors, advantage was taken of the mechanics of reverse transcription to engineer self-inactivating (SIN) HIV-1-derived vectors, which lose the transcriptional capacity of the viral long terminal repeat (LTR) once transferred to target cells. [14] [15] This minimizes the risk of emergence of replication competent recombinants (RCR) and avoids problems linked to promoter interference.
In the retroviral genome, a single RNA molecule that also contains all the necessary cis-acting elements carries all the coding sequences. Biosafety of a vector production system is therefore best achieved by distributing the sequences encoding its various components over as many independent units as possible, to maximize the number of cross-overs that would be required to re-create a RCR. Accordingly, in the latest version of HIV-based packaging system, Gag/Pol, Rev, VSV G and the vector are produced from four separate DNA units. 13 Also, the overlap between vector and helper sequences, having potential for homologous recombination, has been reduced to a few tens of nucleotides. Overall, the combination of a third generation (gag/pol/rev) HIV-1-based packaging system with a SIN vector offers a level of biosafety that even exceeds that of oncoretroviral vectors currently used in the clinics. Importantly, this has been achieved without significant loss of performance compared with the first generation system, at least in the targets tested so far.
Subsequent to the description of the properties of the HIV-1-based gene transfer system, vectors were derived from animal lentiviruses such as simian and feline immunodeficiency viruses and equine infectious anemia virus. [16] [17] [18] Although the development and testing of these other systems is less advanced, it is likely that they will all have the same general properties as their HIV counterpart. But are there any scientific grounds for preferring animal lentivectors to HIV-derived vectors? The proponents of this view usually invoke biosafety, but there are several arguments to the contrary. First, it is conceivable that an HIV-based vector will be more efficient than an animal lentivector in human cells because humans are the natural hosts of HIV. This issue remains to be probed, but several species-specific restrictions have been discovered in the biology of lentiviruses. [19] [20] [21] [22] [23] Second, the genGene Therapy omic complexity of HIV is far greater than that of most other lentiviruses, including feline immunodeficiency virus and equine infectious anemia virus, which each have only six genes instead of the nine present in their human counterpart. Because in all cases a minimum of three genes, gag, pol and rev, will likely be required to generate vector particles efficiently, the multiply attenuated HIV-based packaging system will be the farthest removed from its parental virus. Third, past experience with zoonoses teaches us that the pathogenicity of a given organism is largely unpredictable when it is transferred from its normal animal host into humans. Finally, millions of individuals worldwide have been screened for lentivirus-related diseases. Not only has no pathology been associated with massively deleted forms of HIV-1, but, on the contrary, well documented cases of long-term clinical non-progression have occurred in patients infected with HIV-1 strains that carry genetic alterations far more subtle than those introduced into the third generation HIV-1 packaging system.
The most promising applications of lentiviral vectors
The original demonstration that HIV-based vectors can mediate the efficient in vivo delivery and long-term expression of transgenes was provided in the central nervous system, and lentivectors remain a gene delivery system of choice in this tissue. The stereotactic injection of only a few microliters of vector preparation allows the transduction of tens to hundreds of thousands of neurons in the absence of any significant inflammatory or vectorspecific immune response. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The expression of the foreign protein is long-lasting, at least for the transgenes that have been tested so far. While VSV G-pseudotyped particles target neurons almost exclusively, preliminary evidence indicates that other viral envelopes might permit the more efficient transduction of cells such as astrocytes. In the brain, the striatum, the substantia nigra and the hippocampus are easily targeted, while the susceptibility of other areas remains to be investigated systematically. Neurons of the spinal cord are transducible as well (P Aebischer, personal communication). Studies are in progress in animal models of human neurodegenerative disorders, eg in primates, probing the potential value of the lentivector-mediated transfer of sequences coding for various growth-promoting or anti-apoptotic factors in Parkinson's disease.
Lentivectors also seem to be the vehicles of choice for the genetic modification of retinal cells, and HIV vectormediated gene therapy appears promising for the treatment of recessive forms of inherited retinal degeneration. 25, 26 HIV-based vectors can also efficiently transfer genes in the mammalian cochlea, and may fulfill an important role in the care of patients suffering from hearing impairment refractory to conventional therapy. 27 Lentivectors, at least in their current form, seem comparatively poor at delivering genes in vivo into the liver and muscle. Even though some encouraging results were originally obtained with HIV-based vectors, 28 further experiments have generally revealed disappointingly low efficacies, at least in adult animals. At present, it appears that adenoviral and adeno-associated viral vectors are better suited for these organs.
In contrast, the lympho-hematopoietic system will likely represent one of the most important targets of lentiviral vectors. Indeed, HIV-based vectors can efficiently transduce human CD34 + hematopoietic stem cells (HSCs) in the absence of cytokine stimulation, and these cells are capable of long-term engraftment of non-obese diabetic/severe combined immunodeficient (NOD/ SCID) mice. [29] [30] [31] [32] [33] Furthermore, bone marrow from these primary recipients can repopulate secondary mice with transduced cells, confirming the lentivector-mediated genetic modification of primitive hematopoietic precursors, most probably bona fide stem cells (submitted). Since none of the other currently available gene delivery systems has this ability, lentiviral vectors provide a previously unexplored basis for the study of hematopoiesis and for the gene therapy of inherited and acquired lympho-hematopoietic disorders via the genetic modification of HSCs.
Finally, one promising field of lentivector application is the ex vivo transduction of cells otherwise difficult to transfect. One typical example is the human pancreatic islet cell, 34 but high-efficiency lentivector-mediated gene transfer has been obtained in a very large number of either primary cells or established lines. Such broad capability extends the range of lentivector use far beyond the boundaries of gene therapy, and should facilitate experimentation in many areas of both basic and clinical research.
And now?
In little more than 3 years, much has been accomplished in the design of lentivectors that show a high degree both of biosafety and performance. Exciting new avenues are opened for gene therapy, particularly in situations where the long-term expression of foreign genes is desired in tissues such as the central nervous and lympho-hematopoietic systems.
Based on this premise, it is likely that a lentivector will soon be proposed for a clinical application, probably first for the ex vivo manipulation of cells before their reimplantation in a patient. No high-output, stable packaging cell line is yet available that produces the latest generation of HIV-based vectors. Although this may change soon, one question will otherwise be whether clinicalgrade vector stocks produced by transient transfection are acceptable for patients' use. In parallel, methods of vector production need to be optimized and standardized, and lentivectors should be taken through the usual biosafety controls.
The modest performance so far of lentiviral vectors in the liver and muscle is vexing. These constitute two important targets of gene therapy, either for the treatment of organ-specific diseases or for the systemic production of therapeutic proteins, and explanations should be found and strategies developed to overcome this surprising limitation.
In tissues where lentivectors are highly efficient, today's success should in most cases be considered as only a beginning. For instance, in the lympho-hematopoietic system, transgene expression in stem cells is rarely the final goal. Instead, the lineage specific and regulated production of proteins is most often desired, with requirements that differ greatly according to the nature of the underlying disease. For example, lentivectors best suited for restoring the function of neutrophils in chronic granulomatous disease will likely differ markedly from those mediating the intracellular immunization of T cells and macrophages against HIV infection. Appropriate in vitro and animal models of human diseases will thus need to be utilized to develop and test lentivectors that are tailored for each individual application. Also, the allimportant question of transgene silencing will need to be examined. One hope is that lentivectors, because they are derived from viruses that induce life-long infections, are protected from such a phenomenon. In that respect, the long-term follow-up of rats whose brains were injected with HIV-derived vectors expressing reporter genes is encouraging. Future experiments will determine whether persistence of expression is the rule for other transgenes and in other organs as well.
More generally, if the ability of lentivectors stably to alter the genome of stem cells extends beyond the hematopoietic system, the quest for these elusive progenitors might be facilitated in many tissues. Even simple marking studies might shed light on critical aspects of human ontogeny and might open new possibilities for cell and organ transplantation.
Many issues have still to be resolved, but the transgenes are finally in. The pressure should be kept on, in order to capitalize on what could be a significant leap towards the genetic treatment of many human disorders.
